SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Rallybio Corporation (RLYB) News

Follow Rallybio Corporation (RLYB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol RLYB Asset equity Sector Markets 90 days 4 Last 15.45 Updated Nov 20, 2026, 09:30 PM UTC Open live news feed Open RLYB chart & news
M Avenzo Therapeutics Closes Merger With Rallybio, Alongside $215 Million Placement Avenzo Therapeutics announced the closing of its merger with Rallybio Corporation and referenced a previously announced $215 million concurrent private placement. MNA | Nov 20, 2026, 09:30 PM UTC L Rallybio Announces Reverse Stock Split Tied to Proposed Avenzo Merger Rallybio announced a reverse stock split of its common stock in connection with its proposed merger with Avenzo. EQUITY | Nov 10, 2026, 10:15 PM UTC M Rallybio Reports $2.73 Million Net Loss for 2026 Rallybio reported no revenue and a net loss of $2.73 million in 2026, compared with revenue of $212,000 and net income of $16.02 million in the prior-year period. Diluted loss per share was $0.48, versus earnings per sha EARNINGS | Oct 27, 2026, 12:11 PM UTC L Rallybio's Jonathan Lieber to shift to part-time CFO role Jonathan Lieber will transition to part-time employment while remaining chief financial officer and principal financial officer, effective September 15, 2026. EQUITY | Sep 09, 2026, 08:35 PM UTC